BRIN: Red and White Vaccine Emergency Circulation Permit Targeted Mid-2022 – Head of the National Research and Innovation Agency (BRIN) Laksana Tri Handoko said that the emergency distribution permit for the use of the Red and White Vaccine is targeted to be obtained in mid-2022.

“In real terms, it is likely that we will be ready to get an emergency distribution permit in mid-2022,” said Handoko, quoted by Antara in Jakarta Jakarta, Thursday (2/9).

Handoko said that the fastest progress on the development of the Red and White Vaccine is currently being carried out by a team from the Eijkman Institute for Molecular Biology in collaboration with PT Bio Farma, and a team from Airlangga University in collaboration with PT Biotis.

Eijkman developed vaccine seeds based on recombinant protein sub-units, while Universitas Airlangga developed vaccine seeds based on inactivated or inactivated viruses.

Handoko emphasized that the main target of vaccine development is not to “winner” efficacy. As long as it meets the standards of the World Health Organization (WHO), which is above 50 percent efficacy, the vaccine can already be used.

BRIN focuses on supporting and facilitating researchers and industry partners to achieve scientifically proven targets and meet regulatory standards from the authorities, so that they are ready to be released by related industries.

Therefore, the development of the Red and White Vaccine must be able to meet regulatory standards and obtain an emergency distribution permit like other vaccines. Thus, the Red and White Vaccine can be used for the benefit of the community.

To support the development of the Red and White Vaccine, BRIN focuses on building animal Biosafety Level 3 (BSL-3) facilities for large-scale primates, and good manufacturing practice (GMP) facilities for limited production of vaccine candidates on various platforms for preclinical testing and clinical trials.

read more  Vaccine-Homeland: late and ineffective - Millennium Group

The animal-BSL-3 facility serves as a means to prove the safety and efficacy of vaccine candidates and various drugs being developed. [gil]


Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Never miss any important news. Subscribe to our newsletter.